ROCHESTER, Minn. (KTTC) – A Winona industrial supply company provided assistance to a Wisconsin high school student’s science ...

Lynozyfic is one of two bispecific antibodies Regeneron hopes will lift its oncology business. Meanwhile, IGM is the latest struggling biotech to agree to a buyout deal from Concentra.

Slashing adverse drug reactions through pharmacogenetics and advanced AI could help rehabilitate the pharmaceutical ...

Regeneron Pharmaceuticals has won Food and Drug Administration accelerated approval of its Lynozyfic treatment for certain patients with the blood cancer multiple myeloma.

Previous reports (including ours) said that a company named Regeneron was supposed to be the buyer, but that deal ended up ...

Anne Wojcicki's TTAM Research Institute has received court approval to acquire 23andMe, the genetic testing company she ...

A bankruptcy judge approved the sale of 23andMe's assets and business operations to a nonprofit led by 23andMe’s co-founder ...

In this video, Robert J. Smith, MD, discusses the many treatment options available to patients with atopic dermatitis.

Hundreds of Sewanhaka, New Hyde Park Memorial and Floral Park Memorial High Schools graduates walked across the stage this ...

Stocks in the healthcare industry fell ahead of June's nonfarm payrolls, which economists surveyed by The Wall Street Journal expect to show declining job creation. Centene stock plummeted 40% after ...

An engineered protein turns off the kind of immune cells most likely to damage tissue as part of Type-1 diabetes, hepatitis, ...